Jeffrey Bennett
Concepts (562)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuromyelitis Optica | 89 | 2026 | 140 | 19.080 |
Why?
| | Aquaporin 4 | 62 | 2026 | 101 | 9.080 |
Why?
| | Multiple Sclerosis | 37 | 2026 | 489 | 6.000 |
Why?
| | Autoantibodies | 53 | 2026 | 1509 | 5.070 |
Why?
| | Immunoglobulin G | 53 | 2026 | 892 | 4.300 |
Why?
| | Optic Neuritis | 15 | 2023 | 44 | 3.940 |
Why?
| | Antibodies, Monoclonal, Humanized | 25 | 2026 | 992 | 2.930 |
Why?
| | B-Lymphocytes | 17 | 2026 | 872 | 2.210 |
Why?
| | Astrocytes | 17 | 2026 | 228 | 1.820 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 18 | 2026 | 55 | 1.720 |
Why?
| | Immunologic Factors | 7 | 2026 | 260 | 1.660 |
Why?
| | Optic Nerve | 12 | 2023 | 67 | 1.560 |
Why?
| | Optic Nerve Diseases | 5 | 2022 | 49 | 1.450 |
Why?
| | Remyelination | 2 | 2025 | 15 | 1.440 |
Why?
| | Complement Inactivating Agents | 4 | 2026 | 74 | 1.310 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 3 | 2023 | 28 | 1.310 |
Why?
| | Neuroglia | 5 | 2024 | 174 | 0.980 |
Why?
| | Demyelinating Diseases | 7 | 2020 | 84 | 0.960 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1505 | 0.940 |
Why?
| | Tomography, Optical Coherence | 7 | 2023 | 270 | 0.930 |
Why?
| | Blood-Brain Barrier | 6 | 2026 | 160 | 0.900 |
Why?
| | Brain | 14 | 2026 | 2969 | 0.900 |
Why?
| | Humans | 154 | 2026 | 145763 | 0.900 |
Why?
| | Complement C5 | 1 | 2025 | 33 | 0.900 |
Why?
| | Immunosuppressive Agents | 8 | 2026 | 838 | 0.890 |
Why?
| | Magnetic Resonance Imaging | 16 | 2026 | 3915 | 0.870 |
Why?
| | Macaca mulatta | 8 | 2024 | 186 | 0.840 |
Why?
| | Epitopes | 8 | 2025 | 473 | 0.840 |
Why?
| | Cerebellum | 4 | 2025 | 224 | 0.820 |
Why?
| | Retinal Degeneration | 2 | 2023 | 40 | 0.810 |
Why?
| | Animals | 70 | 2026 | 38097 | 0.800 |
Why?
| | Natalizumab | 4 | 2020 | 41 | 0.780 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 4 | 2023 | 69 | 0.780 |
Why?
| | Complement System Proteins | 7 | 2019 | 314 | 0.780 |
Why?
| | Methylprednisolone | 1 | 2023 | 59 | 0.760 |
Why?
| | Central Nervous System | 6 | 2026 | 282 | 0.750 |
Why?
| | Optic Neuropathy, Ischemic | 4 | 2015 | 31 | 0.740 |
Why?
| | Disease Models, Animal | 17 | 2026 | 4568 | 0.720 |
Why?
| | Immunoglobulin Heavy Chains | 4 | 2015 | 86 | 0.690 |
Why?
| | Autoimmunity | 4 | 2017 | 933 | 0.680 |
Why?
| | Myelin Sheath | 7 | 2025 | 166 | 0.660 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 40 | 0.640 |
Why?
| | Adult | 49 | 2026 | 40872 | 0.620 |
Why?
| | Immunotherapy | 4 | 2020 | 667 | 0.620 |
Why?
| | Mice | 36 | 2026 | 18355 | 0.610 |
Why?
| | Middle Aged | 46 | 2026 | 36302 | 0.590 |
Why?
| | Complement C1q | 1 | 2019 | 32 | 0.580 |
Why?
| | Complement Activation | 4 | 2022 | 399 | 0.580 |
Why?
| | Plasma Cells | 7 | 2017 | 80 | 0.580 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2019 | 24 | 0.570 |
Why?
| | Glial Fibrillary Acidic Protein | 5 | 2024 | 122 | 0.560 |
Why?
| | Pseudotumor Cerebri | 2 | 2016 | 32 | 0.560 |
Why?
| | Cell Membrane | 3 | 2017 | 709 | 0.560 |
Why?
| | Papilledema | 4 | 2023 | 44 | 0.550 |
Why?
| | Inflammation | 11 | 2023 | 2883 | 0.550 |
Why?
| | Aminopyridines | 1 | 2019 | 129 | 0.550 |
Why?
| | Female | 69 | 2026 | 79035 | 0.550 |
Why?
| | Organic Chemicals | 1 | 2019 | 112 | 0.540 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 4 | 2021 | 83 | 0.540 |
Why?
| | Pyrroles | 1 | 2019 | 220 | 0.530 |
Why?
| | Herpesvirus 3, Human | 7 | 2015 | 343 | 0.530 |
Why?
| | Double-Blind Method | 10 | 2025 | 2064 | 0.530 |
Why?
| | Glucocorticoids | 2 | 2019 | 532 | 0.520 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2017 | 50 | 0.520 |
Why?
| | Microglia | 2 | 2019 | 273 | 0.510 |
Why?
| | Disease Management | 2 | 2018 | 653 | 0.500 |
Why?
| | CHO Cells | 8 | 2019 | 169 | 0.500 |
Why?
| | Transverse Sinuses | 1 | 2016 | 9 | 0.500 |
Why?
| | Biomarkers | 13 | 2025 | 4302 | 0.490 |
Why?
| | Antigens, CD19 | 5 | 2022 | 128 | 0.490 |
Why?
| | Registries | 1 | 2025 | 2410 | 0.490 |
Why?
| | Heat-Shock Proteins | 1 | 2017 | 139 | 0.490 |
Why?
| | Spinal Cord | 8 | 2023 | 382 | 0.490 |
Why?
| | Cricetulus | 7 | 2019 | 118 | 0.480 |
Why?
| | Recombinant Proteins | 8 | 2019 | 1368 | 0.480 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2016 | 53 | 0.480 |
Why?
| | Retina | 5 | 2023 | 329 | 0.470 |
Why?
| | Male | 56 | 2026 | 73003 | 0.470 |
Why?
| | Mice, Inbred C57BL | 14 | 2026 | 5992 | 0.450 |
Why?
| | Mutagenesis | 2 | 2019 | 194 | 0.440 |
Why?
| | Cerebral Cortex | 4 | 2026 | 474 | 0.440 |
Why?
| | Stents | 2 | 2016 | 564 | 0.420 |
Why?
| | Herpesvirus 4, Human | 2 | 2012 | 172 | 0.420 |
Why?
| | Giant Cell Arteritis | 5 | 2020 | 48 | 0.420 |
Why?
| | Optic Atrophy | 2 | 2011 | 8 | 0.410 |
Why?
| | Temporal Arteries | 4 | 2015 | 45 | 0.400 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2006 | 156 | 0.400 |
Why?
| | Oligodendroglia | 4 | 2025 | 190 | 0.400 |
Why?
| | Autoantigens | 6 | 2026 | 427 | 0.400 |
Why?
| | Intracranial Hypotension | 2 | 2025 | 65 | 0.390 |
Why?
| | Recurrence | 8 | 2026 | 1139 | 0.380 |
Why?
| | Peptide Fragments | 4 | 2023 | 696 | 0.380 |
Why?
| | Antigens, Viral | 3 | 2015 | 182 | 0.370 |
Why?
| | Flow Cytometry | 9 | 2023 | 1165 | 0.370 |
Why?
| | Rats | 14 | 2026 | 5585 | 0.360 |
Why?
| | Myelin Basic Protein | 6 | 2018 | 44 | 0.360 |
Why?
| | Axons | 2 | 2022 | 204 | 0.360 |
Why?
| | Wolfram Syndrome | 1 | 2011 | 5 | 0.350 |
Why?
| | Retinal Ganglion Cells | 3 | 2016 | 121 | 0.350 |
Why?
| | Visual Acuity | 6 | 2021 | 490 | 0.350 |
Why?
| | Aged | 24 | 2026 | 26215 | 0.340 |
Why?
| | Central Nervous System Infections | 1 | 2011 | 35 | 0.340 |
Why?
| | Hemodynamics | 1 | 2016 | 1118 | 0.340 |
Why?
| | Cricetinae | 6 | 2019 | 305 | 0.340 |
Why?
| | Gene Targeting | 1 | 2011 | 81 | 0.330 |
Why?
| | Organ Culture Techniques | 5 | 2018 | 154 | 0.330 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2012 | 101 | 0.330 |
Why?
| | Nerve Degeneration | 1 | 2010 | 49 | 0.330 |
Why?
| | Stilbenes | 1 | 2010 | 30 | 0.330 |
Why?
| | Prospective Studies | 11 | 2025 | 8075 | 0.320 |
Why?
| | Eye Diseases | 2 | 2020 | 97 | 0.320 |
Why?
| | Nerve Regeneration | 1 | 2010 | 58 | 0.320 |
Why?
| | Young Adult | 17 | 2025 | 14251 | 0.320 |
Why?
| | Nerve Tissue Proteins | 3 | 2014 | 592 | 0.310 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 2 | 2010 | 38 | 0.310 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 4 | 2019 | 21 | 0.300 |
Why?
| | Immune System Phenomena | 1 | 2009 | 3 | 0.300 |
Why?
| | Meningioma | 2 | 2023 | 88 | 0.300 |
Why?
| | Virus Diseases | 1 | 2011 | 216 | 0.290 |
Why?
| | Cell Survival | 2 | 2019 | 1103 | 0.290 |
Why?
| | Adolescent | 18 | 2024 | 22573 | 0.290 |
Why?
| | Somatosensory Cortex | 2 | 2026 | 42 | 0.280 |
Why?
| | Amino Acid Sequence | 7 | 2015 | 2131 | 0.280 |
Why?
| | Nervous System Diseases | 2 | 2020 | 286 | 0.280 |
Why?
| | Rats, Inbred Lew | 7 | 2021 | 105 | 0.270 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2022 | 133 | 0.270 |
Why?
| | Neurology | 2 | 2007 | 117 | 0.260 |
Why?
| | Protein Binding | 7 | 2025 | 2240 | 0.260 |
Why?
| | Ophthalmology | 2 | 2007 | 120 | 0.260 |
Why?
| | Antibodies | 3 | 2017 | 397 | 0.260 |
Why?
| | Peptide Library | 5 | 2025 | 91 | 0.260 |
Why?
| | Neurodegenerative Diseases | 1 | 2009 | 143 | 0.250 |
Why?
| | Oligoclonal Bands | 3 | 2011 | 26 | 0.250 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1997 | 0.250 |
Why?
| | Immunization, Passive | 3 | 2020 | 90 | 0.250 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2006 | 47 | 0.250 |
Why?
| | Immunoglobulins | 2 | 2026 | 163 | 0.240 |
Why?
| | Mutation | 6 | 2019 | 4090 | 0.240 |
Why?
| | Corpus Callosum | 1 | 2006 | 72 | 0.240 |
Why?
| | Transcriptome | 4 | 2020 | 1042 | 0.240 |
Why?
| | Antibody Formation | 1 | 2007 | 288 | 0.240 |
Why?
| | Gyrus Cinguli | 2 | 2024 | 97 | 0.240 |
Why?
| | Endothelial Cells | 2 | 2026 | 877 | 0.230 |
Why?
| | Proteomics | 2 | 2012 | 1188 | 0.230 |
Why?
| | Herpes Zoster | 3 | 2015 | 319 | 0.230 |
Why?
| | Atrophy | 2 | 2023 | 199 | 0.230 |
Why?
| | B-Lymphocyte Subsets | 2 | 2024 | 76 | 0.220 |
Why?
| | Capillaries | 1 | 2026 | 125 | 0.220 |
Why?
| | Immunodominant Epitopes | 2 | 2017 | 27 | 0.220 |
Why?
| | Syndecan-1 | 4 | 2011 | 43 | 0.220 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2025 | 60 | 0.220 |
Why?
| | Myasthenia Gravis | 2 | 2022 | 24 | 0.220 |
Why?
| | Cell Adhesion Molecules | 1 | 2006 | 181 | 0.220 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2025 | 74 | 0.210 |
Why?
| | Retrospective Studies | 12 | 2026 | 17325 | 0.210 |
Why?
| | Lupus Vasculitis, Central Nervous System | 1 | 2024 | 14 | 0.210 |
Why?
| | Acute Disease | 3 | 2018 | 1036 | 0.210 |
Why?
| | Genetic Diseases, Inborn | 1 | 2004 | 45 | 0.210 |
Why?
| | Membrane Proteins | 2 | 2026 | 1166 | 0.210 |
Why?
| | Spastic Paraplegia, Hereditary | 1 | 2024 | 12 | 0.210 |
Why?
| | Cerebellar Ataxia | 1 | 2024 | 13 | 0.210 |
Why?
| | Touch Perception | 1 | 2024 | 17 | 0.200 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2 | 2020 | 28 | 0.200 |
Why?
| | Consciousness | 1 | 2024 | 35 | 0.200 |
Why?
| | Vascular Remodeling | 1 | 2026 | 209 | 0.200 |
Why?
| | Nystagmus, Pathologic | 1 | 2024 | 19 | 0.200 |
Why?
| | Diagnosis, Differential | 6 | 2023 | 1512 | 0.200 |
Why?
| | Blindness, Cortical | 1 | 2003 | 6 | 0.200 |
Why?
| | Neurofilament Proteins | 1 | 2024 | 79 | 0.200 |
Why?
| | Proteolipids | 1 | 2023 | 28 | 0.200 |
Why?
| | Proteoglycans | 1 | 2004 | 112 | 0.200 |
Why?
| | Paraplegia | 1 | 2024 | 60 | 0.200 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2016 | 174 | 0.200 |
Why?
| | Risk Assessment | 4 | 2021 | 3752 | 0.200 |
Why?
| | Epitope Mapping | 4 | 2017 | 61 | 0.190 |
Why?
| | Enzyme Inhibitors | 1 | 2007 | 821 | 0.190 |
Why?
| | Cell Proliferation | 4 | 2026 | 2514 | 0.190 |
Why?
| | Seroconversion | 1 | 2023 | 48 | 0.190 |
Why?
| | Cell Nucleus | 1 | 2026 | 588 | 0.190 |
Why?
| | White Matter | 1 | 2025 | 155 | 0.190 |
Why?
| | Neuroprotection | 1 | 2023 | 46 | 0.190 |
Why?
| | Immune System | 1 | 2004 | 180 | 0.190 |
Why?
| | Lupus Erythematosus, Systemic | 2 | 2023 | 238 | 0.190 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2023 | 147 | 0.190 |
Why?
| | Cells, Cultured | 7 | 2016 | 4151 | 0.180 |
Why?
| | Molecular Sequence Data | 5 | 2011 | 2883 | 0.180 |
Why?
| | Disease Progression | 4 | 2026 | 2865 | 0.180 |
Why?
| | Incidence | 3 | 2025 | 2933 | 0.180 |
Why?
| | Vision Disorders | 2 | 2021 | 179 | 0.180 |
Why?
| | Zika Virus | 1 | 2023 | 136 | 0.180 |
Why?
| | Mice, Transgenic | 5 | 2018 | 2191 | 0.180 |
Why?
| | Hippocampus | 2 | 2021 | 973 | 0.180 |
Why?
| | Gene Expression Profiling | 3 | 2020 | 1777 | 0.180 |
Why?
| | Leukocytes, Mononuclear | 2 | 2023 | 574 | 0.170 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 499 | 0.170 |
Why?
| | Antibody Affinity | 2 | 2019 | 60 | 0.170 |
Why?
| | Protein Isoforms | 4 | 2017 | 399 | 0.170 |
Why?
| | Lipids | 1 | 2026 | 707 | 0.170 |
Why?
| | Patient Reported Outcome Measures | 1 | 2025 | 498 | 0.170 |
Why?
| | Zika Virus Infection | 1 | 2023 | 172 | 0.170 |
Why?
| | Pre-Eclampsia | 1 | 2003 | 206 | 0.170 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2021 | 31 | 0.170 |
Why?
| | Comorbidity | 2 | 2024 | 1662 | 0.170 |
Why?
| | Internationality | 2 | 2019 | 156 | 0.160 |
Why?
| | Immunogenicity, Vaccine | 1 | 2020 | 37 | 0.160 |
Why?
| | Lymphocyte Activation | 2 | 2020 | 1133 | 0.160 |
Why?
| | Schizophrenia | 2 | 2022 | 464 | 0.160 |
Why?
| | Immunoglobulin Light Chains | 2 | 2015 | 52 | 0.160 |
Why?
| | Receptors, Interleukin-6 | 1 | 2020 | 48 | 0.160 |
Why?
| | Azathioprine | 1 | 2020 | 44 | 0.160 |
Why?
| | Nanoparticles | 1 | 2026 | 517 | 0.150 |
Why?
| | Visual Pathways | 3 | 2023 | 61 | 0.150 |
Why?
| | Animals, Newborn | 3 | 2018 | 896 | 0.150 |
Why?
| | Interferon-gamma | 1 | 2023 | 784 | 0.150 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2024 | 782 | 0.150 |
Why?
| | Antibodies, Blocking | 1 | 2019 | 37 | 0.150 |
Why?
| | Myelin Proteins | 2 | 2017 | 45 | 0.150 |
Why?
| | Amygdala | 1 | 2021 | 200 | 0.150 |
Why?
| | Cell Separation | 2 | 2015 | 306 | 0.150 |
Why?
| | Viral Vaccines | 1 | 2020 | 107 | 0.150 |
Why?
| | Steroids | 1 | 2020 | 160 | 0.150 |
Why?
| | Models, Molecular | 3 | 2025 | 1599 | 0.150 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2019 | 17 | 0.150 |
Why?
| | Prevalence | 2 | 2024 | 2874 | 0.150 |
Why?
| | Child | 13 | 2024 | 22739 | 0.150 |
Why?
| | United States | 3 | 2025 | 16123 | 0.140 |
Why?
| | Oxidoreductases | 1 | 2019 | 91 | 0.140 |
Why?
| | Intersectoral Collaboration | 1 | 2019 | 64 | 0.140 |
Why?
| | Glutathione S-Transferase pi | 1 | 2018 | 10 | 0.140 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2018 | 9 | 0.140 |
Why?
| | Treatment Outcome | 11 | 2024 | 11793 | 0.140 |
Why?
| | Cell Lineage | 1 | 2020 | 378 | 0.140 |
Why?
| | Killer Cells, Natural | 3 | 2024 | 481 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2020 | 166 | 0.140 |
Why?
| | Neurogenesis | 3 | 2016 | 157 | 0.140 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.140 |
Why?
| | RNA, Messenger | 1 | 2026 | 2805 | 0.140 |
Why?
| | Immunoglobulin Variable Region | 3 | 2008 | 80 | 0.140 |
Why?
| | Peptides | 2 | 2019 | 998 | 0.140 |
Why?
| | Point Mutation | 1 | 2019 | 241 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 67 | 0.130 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 468 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 289 | 0.130 |
Why?
| | Skull Neoplasms | 1 | 2017 | 21 | 0.130 |
Why?
| | Spatial Analysis | 1 | 2017 | 21 | 0.130 |
Why?
| | Sphenoid Bone | 1 | 2017 | 15 | 0.130 |
Why?
| | Brain Mapping | 3 | 2026 | 542 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2020 | 534 | 0.130 |
Why?
| | Least-Squares Analysis | 1 | 2017 | 73 | 0.130 |
Why?
| | Mice, Knockout | 9 | 2017 | 3130 | 0.130 |
Why?
| | Antibodies, Viral | 4 | 2023 | 674 | 0.130 |
Why?
| | Cohort Studies | 5 | 2022 | 6032 | 0.130 |
Why?
| | Orbital Diseases | 1 | 2017 | 37 | 0.120 |
Why?
| | Albumins | 1 | 2017 | 119 | 0.120 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 104 | 0.120 |
Why?
| | Protein Structure, Secondary | 2 | 2015 | 371 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 923 | 0.120 |
Why?
| | Oculomotor Muscles | 1 | 2017 | 86 | 0.120 |
Why?
| | Fibrinogen | 1 | 2017 | 180 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2020 | 779 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2016 | 5428 | 0.120 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 319 | 0.120 |
Why?
| | HEK293 Cells | 4 | 2022 | 741 | 0.120 |
Why?
| | Microvessels | 1 | 2017 | 97 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 2 | 2021 | 484 | 0.120 |
Why?
| | Interferon-beta | 2 | 2025 | 92 | 0.120 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2022 | 655 | 0.120 |
Why?
| | Ethics, Research | 1 | 2015 | 31 | 0.120 |
Why?
| | Treatment Failure | 1 | 2016 | 360 | 0.110 |
Why?
| | Microscopy, Fluorescence | 1 | 2017 | 408 | 0.110 |
Why?
| | Herpes Zoster Ophthalmicus | 1 | 2015 | 6 | 0.110 |
Why?
| | Eye Infections, Viral | 1 | 2015 | 12 | 0.110 |
Why?
| | Retinal Neurons | 1 | 2015 | 4 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 384 | 0.110 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.110 |
Why?
| | Scanning Laser Polarimetry | 1 | 2014 | 2 | 0.110 |
Why?
| | Molecular Dynamics Simulation | 1 | 2017 | 265 | 0.110 |
Why?
| | Protein Structure, Tertiary | 2 | 2015 | 855 | 0.110 |
Why?
| | Diffusion Tensor Imaging | 1 | 2015 | 78 | 0.110 |
Why?
| | Aged, 80 and over | 8 | 2021 | 8346 | 0.110 |
Why?
| | Plasma Exchange | 1 | 2014 | 18 | 0.110 |
Why?
| | Nerve Fibers | 1 | 2015 | 105 | 0.100 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2011 | 3937 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 979 | 0.100 |
Why?
| | Small Molecule Libraries | 2 | 2013 | 111 | 0.100 |
Why?
| | Rats, Inbred F344 | 2 | 2012 | 268 | 0.100 |
Why?
| | Nuclear Proteins | 1 | 2019 | 740 | 0.100 |
Why?
| | Alanine | 1 | 2015 | 169 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2028 | 0.100 |
Why?
| | Glycine | 1 | 2015 | 186 | 0.100 |
Why?
| | Erythropoietin | 1 | 2014 | 100 | 0.100 |
Why?
| | Placenta Diseases | 1 | 2013 | 20 | 0.100 |
Why?
| | Peptoids | 1 | 2013 | 1 | 0.100 |
Why?
| | Fetal Death | 1 | 2013 | 57 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 2 | 2016 | 2525 | 0.100 |
Why?
| | Antibody Specificity | 2 | 2011 | 179 | 0.100 |
Why?
| | Retinal Necrosis Syndrome, Acute | 1 | 2013 | 7 | 0.100 |
Why?
| | Autism Spectrum Disorder | 2 | 2016 | 423 | 0.090 |
Why?
| | Neurons | 5 | 2024 | 1652 | 0.090 |
Why?
| | Computer Simulation | 1 | 2017 | 1003 | 0.090 |
Why?
| | Biomedical Research | 1 | 2019 | 719 | 0.090 |
Why?
| | Phenotype | 3 | 2020 | 3170 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2024 | 2219 | 0.090 |
Why?
| | Syndrome | 2 | 2019 | 381 | 0.090 |
Why?
| | Cell Membrane Permeability | 1 | 2012 | 88 | 0.090 |
Why?
| | Proteome | 2 | 2015 | 513 | 0.090 |
Why?
| | Multiprotein Complexes | 2 | 2012 | 172 | 0.090 |
Why?
| | Exanthema | 1 | 2013 | 86 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 666 | 0.090 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2012 | 46 | 0.090 |
Why?
| | Antigens, CD20 | 2 | 2023 | 34 | 0.090 |
Why?
| | Area Postrema | 1 | 2011 | 2 | 0.090 |
Why?
| | Glutamate Plasma Membrane Transport Proteins | 1 | 2011 | 7 | 0.090 |
Why?
| | Disability Evaluation | 2 | 2026 | 311 | 0.090 |
Why?
| | Excitatory Amino Acid Transporter 2 | 1 | 2011 | 14 | 0.090 |
Why?
| | Cranial Sinuses | 1 | 2011 | 16 | 0.090 |
Why?
| | Drug Discovery | 1 | 2013 | 153 | 0.090 |
Why?
| | Chromosomes, Human, Pair 4 | 1 | 2011 | 25 | 0.090 |
Why?
| | HLA-DRB1 Chains | 1 | 2012 | 110 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1711 | 0.090 |
Why?
| | Fundus Oculi | 1 | 2011 | 89 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2015 | 731 | 0.090 |
Why?
| | Cerebral Angiography | 2 | 2011 | 119 | 0.090 |
Why?
| | Species Specificity | 2 | 2026 | 546 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2026 | 2967 | 0.080 |
Why?
| | Tissue Culture Techniques | 3 | 2017 | 82 | 0.080 |
Why?
| | Quality of Life | 1 | 2023 | 3210 | 0.080 |
Why?
| | Integrin alpha4beta1 | 2 | 2010 | 8 | 0.080 |
Why?
| | Fluorescein Angiography | 1 | 2011 | 189 | 0.080 |
Why?
| | Vascular Diseases | 1 | 2013 | 252 | 0.080 |
Why?
| | Cell Line | 3 | 2011 | 2823 | 0.080 |
Why?
| | Spinal Puncture | 1 | 2009 | 18 | 0.080 |
Why?
| | Neurosurgical Procedures | 1 | 2011 | 202 | 0.080 |
Why?
| | Risk Factors | 4 | 2016 | 10917 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4329 | 0.070 |
Why?
| | Pregnancy | 5 | 2023 | 7215 | 0.070 |
Why?
| | Research Design | 1 | 2015 | 1139 | 0.070 |
Why?
| | Genes | 1 | 2009 | 228 | 0.070 |
Why?
| | Algorithms | 1 | 2017 | 1850 | 0.070 |
Why?
| | Databases, Factual | 1 | 2015 | 1491 | 0.070 |
Why?
| | Brain Injuries | 1 | 2014 | 507 | 0.070 |
Why?
| | Time Factors | 4 | 2015 | 7133 | 0.070 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 615 | 0.070 |
Why?
| | Blindness | 1 | 2008 | 51 | 0.070 |
Why?
| | Clone Cells | 3 | 2017 | 263 | 0.070 |
Why?
| | Optic Disk | 1 | 2008 | 53 | 0.070 |
Why?
| | Transfection | 3 | 2018 | 927 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3634 | 0.070 |
Why?
| | Antibody-Producing Cells | 1 | 2007 | 29 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2011 | 529 | 0.070 |
Why?
| | Retinal Artery | 1 | 2007 | 17 | 0.070 |
Why?
| | Vision, Low | 1 | 2007 | 16 | 0.070 |
Why?
| | Pregnancy Complications | 1 | 2013 | 603 | 0.070 |
Why?
| | Age of Onset | 2 | 2020 | 557 | 0.060 |
Why?
| | Monitoring, Physiologic | 1 | 2009 | 289 | 0.060 |
Why?
| | Health | 1 | 2007 | 82 | 0.060 |
Why?
| | Molecular Biology | 2 | 2009 | 58 | 0.060 |
Why?
| | von Hippel-Lindau Disease | 1 | 2007 | 12 | 0.060 |
Why?
| | Subacute Sclerosing Panencephalitis | 1 | 2006 | 6 | 0.060 |
Why?
| | Visual Fields | 1 | 2007 | 116 | 0.060 |
Why?
| | Nucleocapsid Proteins | 1 | 2006 | 28 | 0.060 |
Why?
| | Measles virus | 1 | 2006 | 21 | 0.060 |
Why?
| | Vitreous Body | 1 | 2007 | 117 | 0.060 |
Why?
| | Bevacizumab | 1 | 2007 | 168 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2007 | 116 | 0.060 |
Why?
| | Puerperal Disorders | 1 | 2007 | 36 | 0.060 |
Why?
| | Binding, Competitive | 2 | 2019 | 185 | 0.060 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2019 | 39 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2026 | 86 | 0.060 |
Why?
| | Models, Immunological | 1 | 2006 | 99 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2007 | 239 | 0.060 |
Why?
| | Injections, Spinal | 2 | 2016 | 120 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5922 | 0.060 |
Why?
| | Immunologic Memory | 1 | 2007 | 368 | 0.060 |
Why?
| | Spatio-Temporal Analysis | 2 | 2016 | 34 | 0.060 |
Why?
| | Fetus | 1 | 2009 | 804 | 0.050 |
Why?
| | DNA | 1 | 2011 | 1437 | 0.050 |
Why?
| | Myelography | 1 | 2025 | 44 | 0.050 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2025 | 56 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2007 | 552 | 0.050 |
Why?
| | Syndecans | 1 | 2004 | 5 | 0.050 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 3551 | 0.050 |
Why?
| | Complementarity Determining Regions | 1 | 2004 | 54 | 0.050 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2006 | 288 | 0.050 |
Why?
| | Liposomes | 1 | 2026 | 263 | 0.050 |
Why?
| | Motor Neuron Disease | 1 | 2004 | 20 | 0.050 |
Why?
| | Touch | 1 | 2024 | 39 | 0.050 |
Why?
| | Risk | 1 | 2007 | 923 | 0.050 |
Why?
| | Child, Preschool | 4 | 2021 | 11868 | 0.050 |
Why?
| | Fistula | 1 | 2024 | 49 | 0.050 |
Why?
| | Cranial Nerve Diseases | 1 | 2004 | 44 | 0.050 |
Why?
| | Granzymes | 1 | 2024 | 49 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2025 | 2770 | 0.050 |
Why?
| | Ataxia | 1 | 2024 | 69 | 0.050 |
Why?
| | Cryoelectron Microscopy | 1 | 2025 | 222 | 0.050 |
Why?
| | Geniculate Bodies | 1 | 2023 | 22 | 0.050 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2024 | 70 | 0.050 |
Why?
| | Patient Selection | 1 | 2008 | 739 | 0.050 |
Why?
| | Receptors, IgG | 1 | 2023 | 77 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2399 | 0.050 |
Why?
| | Optic Nerve Neoplasms | 1 | 2023 | 12 | 0.050 |
Why?
| | Cerebrovascular Circulation | 1 | 2026 | 290 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2024 | 224 | 0.050 |
Why?
| | Headache | 1 | 2024 | 151 | 0.050 |
Why?
| | Eye Abnormalities | 1 | 2002 | 17 | 0.050 |
Why?
| | Biopsy | 2 | 2017 | 1082 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 2002 | 93 | 0.050 |
Why?
| | Drug Delivery Systems | 1 | 2026 | 381 | 0.050 |
Why?
| | Developmental Biology | 1 | 2002 | 24 | 0.050 |
Why?
| | Genetic Techniques | 1 | 2002 | 66 | 0.050 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 156 | 0.050 |
Why?
| | Receptors, Cholinergic | 1 | 2022 | 41 | 0.040 |
Why?
| | Meningeal Neoplasms | 1 | 2023 | 95 | 0.040 |
Why?
| | Antigens, Surface | 1 | 2022 | 155 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2006 | 1115 | 0.040 |
Why?
| | Primates | 1 | 2022 | 133 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 2 | 2013 | 365 | 0.040 |
Why?
| | Gene Regulatory Networks | 2 | 2015 | 318 | 0.040 |
Why?
| | Eye | 1 | 2002 | 112 | 0.040 |
Why?
| | Binding Sites | 2 | 2017 | 1311 | 0.040 |
Why?
| | Glycoproteins | 1 | 2023 | 354 | 0.040 |
Why?
| | Delphi Technique | 1 | 2023 | 333 | 0.040 |
Why?
| | Evoked Potentials, Visual | 1 | 2021 | 42 | 0.040 |
Why?
| | Encephalitis Viruses, Tick-Borne | 1 | 2020 | 8 | 0.040 |
Why?
| | Age Factors | 2 | 2021 | 3346 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2022 | 343 | 0.040 |
Why?
| | Base Sequence | 1 | 2004 | 2171 | 0.040 |
Why?
| | COS Cells | 2 | 2011 | 177 | 0.040 |
Why?
| | Random Allocation | 1 | 2021 | 365 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 2000 | 0.040 |
Why?
| | Biological Evolution | 1 | 2024 | 468 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 295 | 0.040 |
Why?
| | Immunity, Humoral | 1 | 2020 | 118 | 0.040 |
Why?
| | Aging | 2 | 2024 | 1973 | 0.040 |
Why?
| | Immunomodulation | 1 | 2020 | 99 | 0.040 |
Why?
| | Stiff-Person Syndrome | 1 | 2019 | 14 | 0.040 |
Why?
| | Carrier Proteins | 1 | 2023 | 729 | 0.040 |
Why?
| | Serum | 1 | 2019 | 58 | 0.040 |
Why?
| | Models, Biological | 1 | 2007 | 1764 | 0.040 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2015 | 910 | 0.040 |
Why?
| | Rituximab | 1 | 2020 | 210 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2019 | 165 | 0.040 |
Why?
| | Eye Pain | 1 | 2018 | 6 | 0.040 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2018 | 45 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2016 | 1454 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 971 | 0.030 |
Why?
| | Survival Analysis | 1 | 2021 | 1378 | 0.030 |
Why?
| | Sequence Alignment | 2 | 2009 | 362 | 0.030 |
Why?
| | Protein Conformation, alpha-Helical | 1 | 2017 | 18 | 0.030 |
Why?
| | Antirheumatic Agents | 1 | 2020 | 307 | 0.030 |
Why?
| | Clonal Deletion | 1 | 2017 | 16 | 0.030 |
Why?
| | Self Tolerance | 1 | 2017 | 26 | 0.030 |
Why?
| | Immunoglobulin Class Switching | 1 | 2017 | 21 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2025 | 3416 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1300 | 0.030 |
Why?
| | Hydrogen Bonding | 1 | 2017 | 169 | 0.030 |
Why?
| | Recovery of Function | 1 | 2021 | 716 | 0.030 |
Why?
| | Craniotomy | 1 | 2017 | 84 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 219 | 0.030 |
Why?
| | Signal Transduction | 2 | 2026 | 5223 | 0.030 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2017 | 145 | 0.030 |
Why?
| | Phosphatidylcholines | 1 | 2017 | 131 | 0.030 |
Why?
| | Lipid Bilayers | 1 | 2017 | 103 | 0.030 |
Why?
| | Animals, Outbred Strains | 1 | 2015 | 6 | 0.030 |
Why?
| | Chronic Disease | 1 | 2022 | 1812 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2017 | 205 | 0.030 |
Why?
| | Influenza Vaccines | 1 | 2020 | 534 | 0.030 |
Why?
| | Th17 Cells | 1 | 2016 | 102 | 0.030 |
Why?
| | Neocortex | 1 | 2016 | 49 | 0.030 |
Why?
| | Conserved Sequence | 1 | 2016 | 244 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 849 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 508 | 0.030 |
Why?
| | Microcephaly | 1 | 2016 | 104 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 382 | 0.030 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2017 | 364 | 0.030 |
Why?
| | Leukocytes | 1 | 2016 | 296 | 0.030 |
Why?
| | Thermodynamics | 1 | 2017 | 419 | 0.030 |
Why?
| | Cerebral Arterial Diseases | 1 | 2015 | 50 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2016 | 451 | 0.030 |
Why?
| | Spinal Cord Diseases | 1 | 2014 | 42 | 0.030 |
Why?
| | Spleen | 1 | 2016 | 508 | 0.030 |
Why?
| | Intellectual Disability | 1 | 2016 | 179 | 0.030 |
Why?
| | Calcium Signaling | 1 | 2016 | 245 | 0.030 |
Why?
| | Immune Tolerance | 1 | 2016 | 385 | 0.030 |
Why?
| | CD59 Antigens | 1 | 2014 | 20 | 0.030 |
Why?
| | Nogo Proteins | 1 | 2013 | 10 | 0.030 |
Why?
| | Cell Adhesion Molecules, Neuronal | 1 | 2014 | 42 | 0.030 |
Why?
| | Sodium Channels | 1 | 2014 | 63 | 0.030 |
Why?
| | SOXC Transcription Factors | 1 | 2013 | 9 | 0.030 |
Why?
| | Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 23 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2017 | 673 | 0.020 |
Why?
| | Narcolepsy | 1 | 2013 | 25 | 0.020 |
Why?
| | Multigene Family | 1 | 2013 | 210 | 0.020 |
Why?
| | Immunoglobulin Idiotypes | 1 | 2012 | 28 | 0.020 |
Why?
| | Neurodevelopmental Disorders | 1 | 2016 | 229 | 0.020 |
Why?
| | Pyrans | 1 | 2012 | 7 | 0.020 |
Why?
| | Parkinson Disease | 1 | 2019 | 601 | 0.020 |
Why?
| | Interneurons | 1 | 2013 | 125 | 0.020 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 273 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 469 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 196 | 0.020 |
Why?
| | Surface Plasmon Resonance | 1 | 2012 | 87 | 0.020 |
Why?
| | Molecular Docking Simulation | 1 | 2012 | 119 | 0.020 |
Why?
| | Binding Sites, Antibody | 1 | 2012 | 40 | 0.020 |
Why?
| | Vaccination | 1 | 2020 | 1428 | 0.020 |
Why?
| | Phlebography | 1 | 2011 | 41 | 0.020 |
Why?
| | O Antigens | 1 | 2011 | 8 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2011 | 197 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 200 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2933 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 302 | 0.020 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 563 | 0.020 |
Why?
| | Genome | 1 | 2013 | 305 | 0.020 |
Why?
| | Protein Array Analysis | 1 | 2011 | 56 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 335 | 0.020 |
Why?
| | Ligands | 1 | 2013 | 668 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2011 | 135 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2011 | 234 | 0.020 |
Why?
| | High-Throughput Screening Assays | 1 | 2012 | 177 | 0.020 |
Why?
| | Tubulin | 1 | 2011 | 146 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2011 | 221 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1897 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1062 | 0.020 |
Why?
| | Biological Assay | 1 | 2010 | 132 | 0.020 |
Why?
| | Palmitic Acid | 1 | 2009 | 40 | 0.020 |
Why?
| | Quantum Dots | 1 | 2009 | 37 | 0.020 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 11 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1723 | 0.020 |
Why?
| | Antiviral Agents | 1 | 2015 | 769 | 0.020 |
Why?
| | Water | 1 | 2012 | 447 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 2460 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2009 | 156 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2009 | 251 | 0.020 |
Why?
| | Virion | 1 | 2009 | 108 | 0.020 |
Why?
| | Pyrazoles | 1 | 2012 | 517 | 0.020 |
Why?
| | Genetic Markers | 1 | 2009 | 338 | 0.020 |
Why?
| | Interferon beta-1b | 1 | 2008 | 2 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 762 | 0.020 |
Why?
| | Databases, Genetic | 1 | 2009 | 238 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 14 | 0.020 |
Why?
| | DNA, Viral | 1 | 2009 | 356 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 473 | 0.020 |
Why?
| | Alzheimer Disease | 1 | 2013 | 630 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1261 | 0.010 |
Why?
| | Glioma | 1 | 2010 | 429 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 1146 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2008 | 782 | 0.010 |
Why?
| | Cytokines | 1 | 2013 | 2069 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2010 | 1450 | 0.010 |
Why?
| | Trochlear Nerve Diseases | 1 | 2004 | 8 | 0.010 |
Why?
| | Oculomotor Nerve Diseases | 1 | 2004 | 14 | 0.010 |
Why?
| | Abducens Nerve Diseases | 1 | 2004 | 13 | 0.010 |
Why?
| | Evidence-Based Medicine | 1 | 2008 | 740 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2006 | 778 | 0.010 |
Why?
| | Calcium | 1 | 2009 | 1191 | 0.010 |
Why?
| | Infant | 1 | 2017 | 10090 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2601 | 0.010 |
Why?
| | Computational Biology | 1 | 2006 | 669 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1751 | 0.010 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1582 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2004 | 6085 | 0.010 |
Why?
|
|
Bennett's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|